Shares of Mesoblast Limited (NASDAQ:MESO – Get Free Report) have been given a consensus rating of “Hold” by the six brokerages that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $16.00.
MESO has been the topic of a number of research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Mesoblast in a research report on Thursday, June 20th. Piper Sandler upgraded Mesoblast from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $4.00 to $11.00 in a research report on Tuesday, July 23rd. Finally, StockNews.com downgraded Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday, May 8th.
View Our Latest Stock Analysis on MESO
Institutional Investors Weigh In On Mesoblast
Mesoblast Stock Down 0.3 %
Shares of Mesoblast stock opened at $7.40 on Friday. The stock’s 50-day simple moving average is $7.41 and its 200-day simple moving average is $5.02. Mesoblast has a 52 week low of $1.61 and a 52 week high of $8.66. The company has a market capitalization of $844.93 million, a price-to-earnings ratio of -6.61 and a beta of 3.48.
Mesoblast Company Profile
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Read More
- Five stocks we like better than Mesoblast
- Where Do I Find 52-Week Highs and Lows?
- Why Call Options Volume for These 2 Stocks Spiked Together
- Canada Bond Market Holiday: How to Invest and Trade
- MarketBeat Week in Review – 7/22 – 7/26
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.